China’s Sinopharm COVID-19 vaccine is highly effective against the Delta variant which has become the dominant variant across the world, Sri Lankan researchers have claimed.
According to a study conducted at the Sri Jayewardenepura University, after receiving the two doses of the Sinopharm vaccine, 95% of the study’s participants developed antibodies similar to a naturally infected COVID-19 person.
The two doses of the Sinopharm vaccine also produced neutralizing antibodies in 81.25% of the study’s participants and these antibody levels were also similar to the antibody levels found in an individual after recovering from a natural COVID-19 infection.
Between the age groups of 20 to 40, 98% of the study’s participants developed antibodies against the Delta variant while in the age group of over 60, 93% developed antibodies against the Delta variant.
Prof. Neelika Malavige, Head of the Immunology and Molecular Medicine Department of the Sri Jayewardenepura University, the study is the first of its kind as researchers looked at every possible angle of the immune system from the Sinopharm’s COVID-19 vaccine.
First found in India late last year, the Delta variant has been detected in more than 90 countries worldwide. This dominant version of the Coronavirus is responsible for a recent surge in infections in many countries including the UK, US, Indonesia, and South Korea.